Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308817 | 0.93 | FYN (0.33) | RXRAMAPK14 | |
| SCHEMBL18308807 | 0.85 | HTR7 (0.33) | RARB | |
| SCHEMBL18308780 | 0.84 | RXRA (0.31) | RXRARARAMAPK14 | |
| SCHEMBL18308784 | 0.84 | RXRA (0.31) | RXRARARAMAPK14 | |
| SCHEMBL18308796 | 0.83 | RARA (0.33) | RXRARARA | |
| SCHEMBL18806017 | 0.83 | — | — | |
| SCHEMBL18308815 | 0.81 | ABL1 (0.30) | RXRAMAPK14 | |
| SCHEMBL12635516 | 0.78 | HRH3 (0.38) | RXRA | |
| SCHEMBL12635519 | 0.78 | HRH3 (0.38) | RXRA | |
| SCHEMBL25959372 | 0.77 | HRH3 (0.32) | RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-08-08 | — | — | US | disclosed |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | GMBH, MERCK PATENT (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20160362606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | VCL, ILK, LCP1 | RXRA 2691/4885RARA 2975/4885MAPK14 261/4885 |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, LCP1, MAP1LC3C | RXRA 1974/4885RARA 2062/4885MAPK14 331/4885 |
| US-20160362606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, PLEC, EML4 | RXRA 2009/4885RARA 1744/4885MAPK14 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.